PHG Needs Assessment Calculator Armenia Rhesus Haemolytic Disease of the Newborn

Welcome to the PHG Health Needs Assessment Calculator for Rhesus Haemolytic Disease of the Newborn. The contents of this file are liste

Full name of the sheet	Short name
Country demographic, maternal health and socioeconomic indicators	Demography
Country health service data	HealthServices
RHD Epidemiology 1.1: Country epidemiology	RHD-E1.1
RHD Epidemiology 1.2: International comparison	RHD-E1.2
RHD Epidemiology 2.1: Data on affected pregnancies: Research studies	RHD-E2.1
RHD Epidemiology 2.2: Data on affected pregnancies: Surveillance	RHD-E2.2
RHD Epidemiology 2.3: Data on affected pregnancies: Other sources	RHD-E2.3
RHD Epidemiology 2.4: Summary of affected pregnancies	RHD-E2.4
RHD Epidemiology 2.5: Sub-population variation in affected pregnancies	RHD-E2.5
RHD Epidemiology 3.1: Mortality data: Research studies	RHD-E3.1
RHD Epidemiology 3.2: Mortality data: Vital registration data	RHD-E3.2
RHD Epidemiology 3.3: Mortality data: Other sources	RHD-E3.3
RHD Epidemiology 3.4: Summary mortality estimates	RHD-E3.4
RHD Epidemiology 3.5: Sub-population variation in mortality	RHD-E3.5
RHD Epidemiology 4.1: Population prevalence: Research studies	RHD-E4.1
RHD Epidemiology 4.2: Population prevalence: Other sources	RHD-E4.2
RHD Epidemiology 4.3: Summary of population prevalence	RHD-E4.3
RHD Epidemiology 4.4: Sub-population prevalence variation	RHD-E4.4
RHD Interventions 1: Prenatal screening and treatment	RHD-Interv1
RHD Interventions 2: Newborn screening and treatment	RHD-Interv2
RHD Needs Assessment Calculator 1: Quantitative baseline	RHD-NA1
RHD Needs Assessment Calculator 3: Quantitative assessment of interventions	RHD-NA3

(There is no sheet RHD-NA2.)

Shared Data

Demographic, maternal health and socio-economic indicators

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Number of persons by age-group and sex	Estimates		Your estimates			Chosen estimates			
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4 years	108461	106926	215387			0			0
5-9 years	97806	96112	193918			0			0
10-14 years	109426	107636	217062			0			0
15-19 years	102971	101321	204292			0			0
20-24 years	101885	100033	201918			0			0
25-29 years	93334	88480	181814			0			0
30-34 years	79862	73897	153759			0			0
35-39 years	60504	56002	116506			0			0
40-44 years	41205	40540	81745			0			0
45-49 years	26240	32925	59165			0			0
50-54 years	19308	31889	51197			0			0
55-59 years	16707	26708	43415			0			0
60-64 years	13686	20196	33882			0			0
65+ years	39009	56623	95632			0			0
Total	910404	939288	1849692	0	0	0	0	0	0
Female population aged 15-44 years		460273			-			-	
Data year		2011 reporte	ed in 2001						
Source, Year			UN 2011						

Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.

Ethnic group	Number	% population

Crude birth rate Flevtility tansd (DB) rtaylityr / 1000	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
population	15.20	Unicef, 2013				
Still birth rate (SB): Still births (SB) / year / 1000 total births	14.50	WHO, 2009				
Total births in 1000s (LB+SB) per year	47	Unicef, 2013				
Infant mortality rate: infant deaths / 1000 LB / year	15.6	Unicef, 2013				
Under-5 mortality rate: U5 deaths / 1000 LB / year	17.5	Unicef, 2013				
Percentage births in women >35 years						
Life expectancy at birth (yrs)	74.24	Unicef, 2013				
% of marriages consanguineous						

Materia el le celtie	Estimate	Source, Year	Your	Source,	Chosen	Source,
Maternal health			estimate	Year	estimate	Year
Prenatal visits – at least 1 visit (%)	99.1	Unicef, 2013				
Prenatal visits – at least 4 visits (%)	92.8	Unicef, 2013				
Births attended by skilled health personnel (%)	99.5	Unicef, 2013				
Contraception prevalence rate (%)	54.9	Unicef, 2013				
Unmet need for family planning (%)	13.3	WHO, 2005				
Total fertility rate	1.74	Unicef, 2013				
% home births						
% births at health care services	99.40	Unicef, 2013				
Number of neonata Newaramaticalth by SBA / trained	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
staff						
% neonatal examinations by SBA/ trained staff						

			Your	Source,	Chosen	Source,
Socio-economic indicators	Estimate	Source, Year	estimate	Year	estimate	Year
Gross national income per capita (PPP int. \$)	6140	Unicef, 2013				
% population living on < US\$1 per day	10.6	Unicef, 2013				
Birth registration coverage (%)	99.6	WHO WHO				
Death registration coverage (%)	50-74	2010 , 2008				

LB = live births
PPP = purchasing power parity
SBA = skilled birth attendant

Armenia Shared Data Health Services Data

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Health Expenditure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Per capita total expenditure on health (PPP int. \$)	249.5	WHO 2011				
Total expenditure on health as percentage of GDP	4.3	WHO 2011				
Per capita government expenditure on health (PPP int. \$)	89.4	WHO 2011				
External resources for health as percentage of total expenditure on health	0.7	WHO 2011				
General government expenditure on health as percentage of total expenditure on health	35.8	WHO 2011				
Out-of-pocket expenditure as percentage of private expenditure on health	89.4	WHO 2011				
Private expenditure on health as percentage of total expenditure on health	64.2	WHO 2011				
General government expenditure on health as percentage of total government expenditure	5.8	WHO 2011				

Health Workforce	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
			estimate	I eai	estimate	I eai
Number of nursing and midwifery personnel	14601	WHO, 2007				
Nursing and midwifery personnel density (per 10,000 population)	48.7	WHO, 2007				
Number of physicians	11088	WHO, 2007				
Physician density (per 10,000 population)	36.97	WHO, 2007				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						
Number of paediatric neurosurgeons						
Number of clinical geneticists						
Number of genetic counsellors						
Number of community health workers						
Number of skilled birth attendants (SBA)						

Density of SBA			
Number of lab staff providing cytogenetic testing			
Number of lab staff providing molecular genetics			
Number of lab staff providing biochemical tests for genetics			
Number of skilled health attendants			

Infrastructure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of maternity units		100		1 00		100
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facillities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity GDP = gross domestic product SBA = skilled birth attendant CD = congenital disorders Armenia
Rhesus Haemolytic Disease of the Newborn
RHD Epidemiology 1.1: Country epidemiology

Epidemiological indicator Your estimates Range PHGDB minimum Chosen Range Source estimates estimates Year of estimate Prevalence at birth and by age-group (/1000) Live birth prevalence (LB) 0.36 Stillbirth prevalence (SB) 0.36 Total birth prevalence (LB+SB) 0.72 All age groups <1 year olds 1-4 year olds 5-14 year olds 15-44 year olds 45+ year olds Number of cases by age group Annual live births 20 All age groups <1 year olds 1-4 year olds 5-14 year olds 15-44 year olds 45+ year olds No. of cases by level of impairment No or minor disability Moderate disability Severe disability Mortality and morbidity Mean life expectancy (yrs) 22 11 No. deaths < 1yr No. deaths 1-4 yrs 15 No. deaths < 5 yrs Infant mortality / 1000 LB 0.23 Under-5 mortality / 1000 LB 0.31 Years of life lost

Armenia
Rhesus Haemolytic Disease of the Newborn
RHD Epidemiology 1.2: International comparison

	Your chosen		Comparison		
Epidemiological indicator	estimates	Country	Region	World	
Prevalence at birth and by age-group (/1000 p	people)		(Asia, Central)		
Live birth prevalence (LB)		0.36	0.88	0.25	
Stillbirth prevalence (SB)		0.36			
Total birth prevalence (LB+SB)		0.72	0.88	0.25	
All age groups					
<1 year olds					
1-4 year olds					
5-14 year olds					
15-44 year olds					
45+ year olds					
Number of cases by age-group					
Annual live births		20	1474	33850	
All age groups					
<1 year olds					
1-4 year olds					
5-14 year olds					
15-44 year olds					
45+ year olds					
No. cases by level of impairment					
No or minor disability					
Moderate disability					
Severe disability					
Mortality and morbidity					
Mean life expectancy (yrs)		22	11.66	25.26	
No. deaths < 1yr		11	959	21195	
No. deaths 1-4 yrs		4	320	7064	
No. deaths < 5 yrs		15	1279	28259	
Infant mortality / 1000 LB		0.23	0.65	0.63	
Under-5 mortality / 1000 LB		0.31	0.87	0.83	
Years of life lost					

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 2.1: Data on affected pregnancies: Research studies

Study author, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies listed above (or in section RHD-E2.1 of the Tool), enter the best estimates for the prevalence of affected births and terminations in the country, and a range of values to reflect uncertainty or within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	LB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of affected stillbirths	SB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 2.2: Data on affected pregnancies: Surveillance

Based on surveillance data, enter the best estimates for the prevalence of the condition in live births and still births. Give a range of values to reflect uncertainty and within-country variation, and use comments for information on data quality, uncertainty and representativeness.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	Birth prevalence / 1000	Comments
Best estimate			
Lower estimate			
Higher estimate			

Estimates for the total country/territory	Number of affected stillbirths	Stillbirth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 2.3: Data on affected pregnancies: Other sources

	Source 1:	Source 2:	Notes
Enter year and source of data – use last year with information available.			
Basic Numbers			
Number of affected live births / year, from data source			
Total number of live births / year, from data source			
Number of affected still births / year, from data source			
Total number of stillbirths / year, from data source			
Total number of affected births / year (live and still)		0	
Total number of births / year, from data source		0 0	
Total number of women aged 15-44]
Live birth prevalence: recorded and estimated			
Recorded live birth prevalence (affected recorded live births / 1000 recorded total births)	#DIV/	0! #DIV/0!	
Estimated completeness of recording: what proportion of true affected live births in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded live births (number of recorded live births / total live births in country or territory)			Range: 0 to 1
Estimated live birth prevalence (recorded prevalence / completeness)	#DIV/)! #DIV/0!	
Estimated true number of affected live births in data source (number of recorded affected live births / completeness)	#DIV/	0! #DIV/0!	
Estimated number of affected live births in total population (number of affected live births from data source / (coverage x completeness))	#DIV/)! #DIV/0!	
Stillbirth prevalence: recorded and estimated]
Recorded stillbirth prevalence (affected recorded still births / 1000 recorded total births)	#DIV/)! #DIV/0!	
Estimated completeness of recording: what proportion of true affected stillbirths in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded stillbirths (number of recorded still births / total still births in country or territory)			Range: 0 to 1
Estimated stillbirth prevalence (recorded prevalence / completeness)	#DIV/	0! #DIV/0!	
Estimated true number of affected stillbirths in data source (number of recorded affected still births / completeness)	#DIV/)! #DIV/0!	
Estimated number of affected stillbirths in total population (number of affected still births from data source / (coverage x completeness))	#DIV/)! #DIV/0!	

Based on the sources above, enter the best prevalence estimates for your population, and a range of values to reflect uncertainty of estimates and within country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the whole country/territory	Number of affected live births	LB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of affected still births	SB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 2.4: Summary of affected pregnancies

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Number of annual affected live births	•		20			
Annual birth prevalence / 1000 TB			0.36			
Number of annual affected still births	3					
Stillbirth prevalence / 1000 TB/year			0.36			

If there are specific sub-types of condition, you can repeat this exercise below. However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 2.5: Sub-population variation in affected pregnancies

If the birth prevalence rates vary by population sub-group (e.g. geographically or by another factor), indicate any population groups with different prevalence estimates from the whole population and describe reasons for variation. If a group is substantially different from the general population, you may wish to conduct a needs assessment for that

Population sub- group	Number of affected live births	LB prevalence / 1000 TB	Reason for variation

Population sub- group	Number of affected stillbirths	SB prevalence / 1000 TB	Reason for variation

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 3.1: Mortality data: Research studies

Source, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for the specific mortality by age-group e.g. infant, under-5s, etc., as appropriate, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Mortality estimates	Number of deaths	Ratio (deaths / 1000 LB)	Comments
Neonatal group (<28 days)			
Best estimate			
Lower estimate			
Higher estimate			
Infant group (<1 year)			
Best estimate			
Lower estimate			
Higher estimate			
Under-5 group (<5 years)			
Best estimate			
Lower estimate			
Higher estimate			
Other age group:			
Best estimate			
Lower estimate			
Higher estimate			

LB = live births

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 3.2: Mortality data: Vital registration data

Fill in the blank cells based on your vital registration data.	
Enter year and source of data	
Registered data	
Total registered live births	
Registered condition-specific neonatal deaths (first 28 days of life)	
Registered condition-specific infant deaths (first year of life)	
Registered condition-specific under-5 deaths (first 5 years of life)	
Registered condition-specific neonatal mortality ratio	#DIV/0!
(condition-specific neonatal deaths / 1000 live births in the same year)	
Registered condition-specific infant mortality (condition-specific infant deaths / 1000 live births in the	#DIV/0!
Registered condition-specific under-5 mortality (condition-specific under-5 deaths / 1000 live births in the	#DIV/0!
same year)	

Adjustment for under-ascertainment of cause of death and sub-registration of deaths: Enter estimates in the highlighted cells. It is not always possible to adjust the estimates, in which case you may give the value '1', accepting that the estimates in these cases will usually be biased towards low values. (Or you may move to the next section.)

It is assumed that under-ascertainment is stable across age-groups; if ascertainment varies by age-group, you could use separate estimates for each age group.

Estimated completeness of recording: what proportion of deaths in affected persons were registered as	
թեթին ation coverage: what proportion of the total country/territory population is covered by the vital	
Deliatration (population coverage x completeness)	0
Estimated values for the total country/ territory population	
Estimated number of live births in total population	#DIV/0!
Estimated number of neonatal deaths in total population (number of deaths registered in neonatal period / ascertainment)	#DIV/0!
Estimated number of infant deaths in total population (number of deaths registered in first year of life / ascertainment)	#DIV/0!
Estimated number of under-5 deaths in total population (number of deaths registered in under-5s / ascertainment)	#DIV/0!
Estimated neonatal mortality ratio (estimated neonatal deaths / 1000 live births)	#DIV/0!
Estimated infant mortality ratio (estimated infant deaths / 1000 live births)	#DIV/0!
Estimated under-5 mortality ratio (estimated under-5 deaths / 1000 live births)	#DIV/0!

Range: 0 to 1 Range: 0 to 1

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 3.3: Mortality data: Other sources

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Neonatal mortal	ity	Infant mortality		Under-5 mortality	
Estimates for the total country/territory	Value	Ratio/1000 LB	Value	Ratio/1000 LB	Value	Ratio/1000 LB
Best estimate						
Lower estimate						
Higher estimate						

Armenia
Rhesus Haemolytic Disease of the Newborn
RHD Epidemiology 3.4: Summary mortality estimates

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of data collection						
Number of annual deaths in affected persons						
Number of annual live births (in 1000s)			47			
Number of annual affected neonatal deaths			10			
Number of affected neonatal deaths / 1000 LB			0.22			
Number of annual affected infant deaths			11			
Number of affected infant deaths / 1000 LB			0.23			
Number of annual affected under-5 deaths	ĺ		15			
Number of affected under-5 deaths / 1000 LB			0.31			
Mean life expectancy at birth in affected	Ì		22			
9999 Indicators (e.g. survival following surgical procedure, etc)						

Armenia
Rhesus Haemolytic Disease of the Newborn
RHD Epidemiology 3.5: Sub-population variation in mortality

Age group: neonatal Population sub-group	Cause-specific, group-specific neonatal mortality ratio / 1000 LB	Reason for variation

Age group: infant Population sub-group	Cause-specific, group-specific infant mortality ratio / 1000 LB	Reason for variation

			Reason for variation
Population sub-group	affected persons	under-5 mortality ratio / 1000 LB	

Age group:		Cause-specific, group-specific	Reason for variation	
Population sub-group	affected persons	mortality ratio / 1000 population		

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 4.1: Population prevalence: Research studies

Study, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for population prevalence, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 4.2: Population prevalence: Other sources

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

Armenia
Rhesus Haemolytic Disease of the Newborn
RHD Epidemiology 4.3: Summary of population prevalence

Source of estimates	Estimated total population number of affected persons	Range	Estimated total population prevalence / 1000 persons	Range
1				
2				
3				
4				
5				
PHGDB				
Chosen estimates				

Rhesus Haemolytic Disease of the Newborn

RHD Epidemiology 4.4: Sub-population prevalence variation

Population sub-group	Total number of people in population sub-group	Population prevalence per 1000 people	Reason for variation
		#DIV/0!	

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Formula in column D: Number of affected people/ (Total number of people in population subgroup/1000)

Rhesus Haemolytic Disease of the Newborn

SCD Intervention 1:Effects of prenatal screening and treatment

Baseline prevalence of RHD per 1000 TB		
Variables		
Coverage of prenatal screening		Range: 0 to
Proportion of RhD negative women receiving anti-D		Range: 0 to
Effectiveness of anti-D in RhD negative women		Range: 0 to
Results		
% prevalence reduction due to PNS & treatment ¹	0%	
Prevalence reduction due to PNS & treatment, per 1000 TB ²	0.000	
Final prevalence of RHD-affected live births and still births		
after PNS & treatment, per 1000 TB³	0.000	

RHD = Rhesus Haemolytic Disease of the Newborn

PNS = prenatal screening

¹ (Coverage of PNS X Proportion of women receiving anti-D) X Effectiveness of anti-D

²% prevalence reduction due to PNS and treatment X Baseline prevalence of RHD

³ Baseline prevalence of RHD – Prevalence reduction due to PNS and treatment

Rhesus Haemolytic Disease of the Newborn

RHD Intervention 2:Effects of NBS and management on Rhesus Haemolytic Disease of the Newborn

Baseline birth prevalence of RHD, per 1000 LB		
Variables		
Coverage of newborn screening		Range: 0 to 1
Proportion of positive-screened patients receiving treatment		Range: 0 to 1
Effectiveness of treatment		Range: 0 to 1
Results		
Proportional reduction of uncontrolled cases through NBS and treatment ¹	0	
Prevalence of uncontrolled RHD deficiency after newborn screening and treatment, per 1000 LB ²	0	

LB = live births

NBS = newborn screening

RH 9 เนื้อเกิด เลือน เล

¹Coverage of newborn screening X Proportion of screen-positive cases receiving treatment X Effectiveness of treatment

²Baseline birth prevalence – (Proportional reduction of uncontrolled cases of RHD X Baseline birth prevalence)

Rhesus Haemolytic Disease of the Newborn

RHD Needs Assessment Calculator 1: Quantitative baseline

Table RHD-NA1a Burden of Rhesus Haemolytic Disease of the Newborn in pregnancy, at birth and at population level

	Chosen estimates			Notes
Indicator	Number (n)		Range of prevalence (/1000 TB)	
Annual affected live births (LB)	0	0	0	Drawn from sheet E2.4
Annual affected stillbirths (SB)	0	0	0	Drawn from sheet E2.4
Annual affected births (LB+SB)	0	0		Drawn from sheet E2.4
Annual affected persons (all age groups)	0	0	0	Drawn from sheet E1.1

Table RCD-NA1b Rhesus Haemolytic Disease of the Newborn mortality indicators

	Chosen estimates			Notes
Indicator	Number (n)	I .	Range of prevalence (/1000 TB)	
Annual overall mortality	0			Drawn from sheet E3.4
Annual neonatal mortality	0	0	0	Drawn from sheet E3.4
Annual infant mortality	0	0	0	Drawn from sheet E3.4
Annual under-5 mortality	0	0	0	Drawn from sheet E3.4
Mean life expectancy at birth among affected people	0		0	Drawn from sheet E3.4

Rhesus Haemolytic Disease of the Newborn

RHD Needs Assessment Calculator 3: Quantitative assessment of interventions

Table SCD-NA3a	-	Estimated prevalence in the absence of interventions for Sickle Cell Disease		
Indicator	Number (n)	Prevalence (n/1000)		
Potential live births				
Potential still births				

Table RHD-NA3b	Current situation in relation to interventions before birth			
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 LB	
Effect of family planning, education				
Effect of anti D prophylaxis				
Effect of prenatal diagnosis and treatment				
Effect of neonatal diagnosis				
Effect of treatment of newborn				
Overall effect				

Table RHD-NA3c	Target situation in relation	Target situation in relation to interventions before birth			
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 LB		
Effect of family planning, education					
Effect of anti D prophylaxis					
Effect of prenatal diagnosis and treatment					
Effect of neonatal diagnosis					
Effect of treatment of newborn					
Overall effect					

Table RHD-NA3d	Current situation in	Current situation in relation to interventions after birth		
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 LB	
Newborn diagnosis				
Phototherapy				
Blood transfusion				
Social care and support				
Overall effect				

Table RHD-NA3e	Target situation in	Target situation in relation to interventions after birth				
Intervention	Coverage (%)	Coverage (%) Cases managed (n) Cases managed				
Newborn diagnosis						
Phototherapy						
Blood transfusion						
Social care and support						
Overall effect						

Table RHD-NA3f	Current and desired or	ıtcomes		
	Current situation	Current situation		
Indicator	Annual number (n)	Incidence (n/1000)	Annual number (n)	Incidence (n/1000)
Estimated affected pregnancies				·
Live births (LB)		0	0	
Still births (SB)		0	0	
All births (LB+SB)		0	0	
Estimated population prevalence		·		
All age groups				
Estimated mortality	·			
Neonatal deaths		0	0	
Infant deaths		0	0	
Under-5 deaths		0	0	